Jak-Stat Signaling Pathway Related Gene Expressions and Blood Biochemical indicators in Acute Promyelocytic Leukemia

Acute promyelocytic leukemia (APL) is a type of acute leukemia, which has the highest death rate among blood cancers and caused by a specific (15; 17) chromosomal translocation, resulting in a fusion gene PML/RARα. Klotho gene plays a role in preventing aging, inflammation and cancer. CTLA4, PD1 and...

Full description

Saved in:
Bibliographic Details
Main Authors: Bui, Kieu Trang, Nguyen, Thi Xuan
Format: Article
Language:English
Published: H. : ĐHQGHN 2020
Subjects:
PD1
Online Access:http://repository.vnu.edu.vn/handle/VNU_123/74883
https://doi.org/10.25073/2588-1132/vnumps.4197
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Vietnam National University, Hanoi
Language: English
Description
Summary:Acute promyelocytic leukemia (APL) is a type of acute leukemia, which has the highest death rate among blood cancers and caused by a specific (15; 17) chromosomal translocation, resulting in a fusion gene PML/RARα. Klotho gene plays a role in preventing aging, inflammation and cancer. CTLA4, PD1 and LAG3 are immunosuppressive receptors located on surface of T cells and considered as a negative regulation of immune response. These genes regulate immune cell activity through several signalling moleculars such as STATs and NF-κB. In this study, to additionally determine the difference between APL and other leukemia, we performed experiments to measure mRNA expression of above genes by using realtime-PCR. Results showed that mRNA levels of KL, CTLA4, PD1 and LAG3 genes were lower, while expressions of STAT1, STAT3, STAT5 and STAT6 genes were significantly higher in APL patients than healthy controls. In addition, IκB-α gene expression was unaltered on APL cells. The results of this study would partially contribute to an understanding of the differences in JAK-STAT signaling associated gene expressions between APL and other leukemia groups. This is important to apply for effective chemotherapy for each type of leukemia.